Coronavirus Resources:
BARDA’s Rapidly Expanding
COVID-19 Medical Countermeasure Portfolio
BARDA has a proven track record of responding to pandemics and developing lifesaving medical countermeasures. We are rapidly executing new partnerships and building a robust COVID-19 MCM Portfolio because Americans deserve to have safe, effective medical products.
This page is updated regularly, but may not include all awards
- All
- Vaccines
- Diagnostics
- Therapeutics
- Rapidly Deployable Capabilities
- Other
Vaccines
Diagnostics
Therapeutics
RDC
Other
Do you have a product for COVID-19 that should be added to the BARDA Portfolio? Submit a request today so BARDA can learn about your product.
BARDA'S Impact of Diagnostic Investments
Rapidly deploying test kits to Americans
82.4M+
Diagnostic Test Kits Shipped by Partners
*as of January 08, 2021